SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Art collage, coins, and arrow up on the red and paper background. Concept of business and financial growth.
Obesity
Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss
Structure’s aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech’s stock up nearly 103% as markets closed on Monday.
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
Infectious disease
Assembly’s Antivirals Show ‘Striking’ Drop in Lesions, Viral Shedding in Early Genital Herpes Study
A mid-stage study for ABI-5366 will begin mid next year, while Assembly continues to assess the Phase II potential of ABI-1179.
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Orlando, Florida
Cancer
ASH25: CAR-T Leaders Gilead, J&J Show in Multiple Myeloma; Fulcrum Rises on Sickle Cell Data
The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare diseases.
December 8, 2025
 · 
5 min read
 · 
Tristan Manalac
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Duchenne muscular dystrophy
Dyne’s Exon Skipper Delivers ‘Best Ever’ Functional Outcomes in Early DMD Study
Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for this treatment class, Stifel analysts said.
December 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Poznan, Poland – October 29, 2020: The Glaxosmithkline headquarters office building in Poznan. LOGO. GaxoSmithKline also called GSK is a British pharmaceutical company.
Cancer
GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya
GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated the partnership.
December 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neuroscience
Biogen, Stoke Boost Epilepsy Drug’s Blockbuster Potential With Early Seizure Reduction Data
Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 billion to $4 billion.
December 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Red round circle with a pause button or icon against yellow background.
Regulatory
FDA Pauses Denali’s Pompe Plans Due to Preclinical Safety Signals
Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 for Pompe disease.
December 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Brain neuro cell growth or damaging drawing with texture shading illustration isolated on dark background
Neuroscience
Praxis Ends Epilepsy Study Early Due to Strong Results, Heads to FDA
Praxis Precision Medicines has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug candidate ulixacaltamide, for which an approval application is slated for early 2026.
December 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Business people shaking hand in China.
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
The partnership will focus on Crescent’s PD-1/VEGF inhibitor CR-001 and Kelun-Biotech’s SKB105, both of which the companies plan to push into Phase I/II development for solid tumors early next year.
December 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Policy
FDA Eyes Higher User Fees for Companies Holding Phase I Studies Abroad
Companies who run their early-stage clinical development outside the U.S. would “experience higher fees” according to an FDA proposal made during the negotiation process for the eighth cycle of the user fee program.
December 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Vaccines
FDA To Provide Further Data on 10 Alleged Pediatric Deaths Linked to COVID-19 Vaccines By End of Month
Last week, Center for Biologics Evaluation and Research Director Vinay Prasad claimed in an internal memo—without providing evidence—that COVID-19 vaccines were responsible for the deaths of 10 children between 2021 and 2024.
December 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Silver Spring, MD, USA 11/10/2020: Exterior view of the headquarters of US Food and Drug Administration (FDA). This federal agency approves medications, vaccines and food additives for human use.
Regulatory
COVID Contrarian Tracy Beth Høeg Named as FDA’s Acting CDER Chief
Høeg is the fifth person to lead the Center for Drug Evaluation and Research this year.
December 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Bristol Myers Squibb office in California
Alzheimer’s disease
BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study
Analysts had noted “unease” from investors regarding the state of the Phase III ADEPT-2 trial, with BMS at one point telling Leerink Partners that the reopening of enrollment would be a “significant development.”
December 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neuroscience
Harmony’s Dravet Drug Halves Monthly Seizures in Late-Stage Study
The Phase III, open-label extension study suggests EPX-100 has a “positive” risk/benefit profile for the treatment of Dravet syndrome, analysts at H.C. Wainwright & Co. said Tuesday.
December 3, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Regulatory
FDA Moves to Cut Back on Testing Antibodies on Primates
For certain monospecific antibodies, three-month toxicology studies plus other supportive evidence will suffice, eliminating the need for six-month testing.
December 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More